Pharmaceutical compositions containing angiogenic activators
The invention relates to therapeutic compositions used in the field of angiogenesis, comprising nucleotide sequences of genes, the involvement of said genes in the angiogenesis mechanism having been demonstrated by the Applicant, and including the complementary sequences thereof, the antisense sequences of same, polypeptide sequences coded by the coding parts of the aforementioned genes and antibodies that are directed against said polypeptide sequences. The invention also relates to genetically-modified cells that underexpress or overexpress the above-mentioned genes and to therapeutic compositions containing said cells, which are used to treat angiogenic disorders. Moreover, the invention relates to methods of diagnosing and/or prognosticating antigenic disorders and to novel methods of screening active compounds in the treatment of said disorders.
1. A pharmaceutical composition comprising a pharmaceutically acceptable carrier and a pharmaceutically effective amount of a polypeptide selected from the group consisting of the polypeptide of the amino acid sequence shown in SEQ ID NO: 58, a polypeptide having an amino acid sequence starting at about residue 1 and ending at about residue 217 of the amino acid sequence shown in SEQ ID NO: 58 and polypeptide fragment thereof; where said polypeptide or fragment thereof activates angiogenesis.
2. The pharmaceutical composition of claim 1 , where the polypeptide consists of amino acid residues 2 to 217 shown in SEQ ID NO: 58.
3. A pharmaceutical composition comprising a pharmaceutically acceptable carrier and a pharmaceutically effective amount of a polypeptide consisting of amino acid residues 1 to 217 shown in SEQ ID NO: 58; where said polypeptide activates angiogenesis.